Merck & Co., Inc. Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31)
Merck & Co., Inc. (MRK) had Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) of $65.00 million as of 2013-06-30, per its 10-Q filed 2013-08-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 · last filed 2013-08-07
- 2013-06-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $65.00M.
- 2013-03-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $6.00M.
- 2012-12-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $6.00M.
- 2012-09-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $3.00M.
| Period end | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $65.00M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $6.00M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $6.00M 10-Q · filed 2013-08-07 |
| 2012-09-30 | $3.00M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $3.00M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $3.00M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $10.00M 10-K · filed 2013-02-28 |
| 2011-09-30 | $8.00M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $4.00M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $16.00M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |